Brief: Anixa and Moffitt Complete Fourth CAR-T Dosing in Ovarian Cancer Trial; Patients Exceed Survival Benchmarks
08/09/2025 13:34
Sept 8 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES AND MOFFITT CANCER CENTER COMPLETE DOSING OF FOURTH COHORT IN OVARIAN CANCER CAR-T CLINICAL TRIAL; MULTIPLE PATIENTS SURPASSING MEDIAN EXPECTED SURVIVAL Source text: ID:nPn1NlxlZa Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine